

Cancer Vaccines Market, Pipeline Analysis Report 2020

https://marketpublishers.com/r/C11B00AA8E60EN.html

Date: June 2020

Pages: 115

Price: US\$ 1,590.00 (Single User License)

ID: C11B00AA8E60EN

Abstracts

"Global Cancer Vaccines market size is expected to surpass US\$ 8.5 Billion by 2025"

Report Scope:

Detailed Insights of the Introduction to Cancer Vaccines and Mechanism of Cancer Vaccines

The Market Size of the Global Cancer Vaccines Market with Five Years Forecast

The Market Size of the 4 Leading Cancer Vaccines with Five Years Forecast

Provides Comprehensive Insights on the Funding of the Cancer Vaccines Research

Investigates the Key Growth Drivers and Restraints of the Global Cancer Vaccines Market

Provides Key Trends with Respect to Collaboration Deals, Merger & Acquisitions, Partnership Deals, and Licensing Agreement

Detailed Insights of the Regulatory Framework Including the Approval Process and an Overview of the Regulatory Authorities in the United States, EU, and Japan

A Comprehensive List of the Key Players Along with the Analysis of their



Current Vaccines Portfolios, Promising Vaccines in the Clinical Development, Sales Value Analysis, and Recent Development

An Insightful Analysis of the Emerging Players Along with the Analysis of their Promising Vaccines in the Clinical Development, Phase, Platform Technology, and Recent Development

"Cancer Vaccines Market, Pipeline Analysis Report, 2020" provides a comprehensive analysis of the fast-evolving, high-growth global cancer vaccines market. The report offers the foremost up-to-date industry data on the specific market situation and future outlook for the global cancer vaccines market. The report provides historical market data for 2015 – 2019, and forecasts from 2020 till 2025.

The report contains a granular evaluation of the prevailing enterprise conditions, market demands, reveal facts in the marketplace, revenues, and offers forecasts through 2025. The report presents clear perception into current and future developments of the global cancer vaccines market.

The report explores detailed insights into the introduction to cancer vaccines and the mechanism of cancer vaccines. The report additionally provides a detailed evaluation of the leading 4 key marketed cancer vaccines market assessments globally, data from 2015 to 2019, and forecasts to 2025. The report reviews a clear insight into the funding of the cancer vaccines studies. The report additionally investigates special insights about the regulatory landscape which include the approval system and an overview of the regulatory authorities in the United States, EU, and Japan.

Key developments of collaboration, partnerships, merger & acquisition, and licensing settlement are analyzed with details. The report additionally examines the principle marketplace growth drivers and restraining forces and also offers an all-round future outlook.

The report concludes with the profiles of the key players in the global cancer vaccines market. The key players are evaluated on various parameters such as business overview, vaccines portfolio, vaccines revenue analysis, and recent development.


Other emerging players are making novel era-based vaccines that are in all possibility to have an effect on the market share during the forecast duration. The emerging players are evaluated on various parameters such as business overview, promising



Gardasil/Gardasil 9

vaccines in the clinical development with the current stage of clinical evaluation, vaccines target, platform technology, and recent developments.

The following 4 leading vaccines of the global cancer vaccines market are detailed with market size and five-year forecast:





ViciniVax

ImmuneTune
Treos Bio Limited
EpiThany
CureVac AG
DCprime
Vaximm AG
AdaptVac
MimiVax LLC
Agenus, Inc
AlphaVax, Inc
Genexine
Globelmmune, Inc
Ubivac, Inc
Vaccinogen, Inc
Genocea Biosciences, Inc
Northwest Biotherapeutics, Inc
OncBioMune Pharmaceuticals, Inc
Inovio Pharmaceuticals, Inc



Enochian Biosciences Eu Biologics Co., Ltd. **EVOQ Therapeutics** Heat Biologics, Inc Scancell Holdings PLC Anixa Biosciences, Inc. PDC*line Pharma Elios Therapeutics, LLC **OSE** Immunotherapeutics The Report Helps Solution the Following Questions: What is the current size of the overall global cancer vaccines market? How much will this market be worth from 2020 to 2025? What are the key marketed cancer vaccines? What are their revenue potentials to 2025? What are the main drivers and restraints in the global cancer vaccines market?

What are the major deals happenings in the global cancer vaccines market?

Who are the top market players and what are their happenings, vaccines

revenue, current developments, and scenarios?

What are some of the most prominent cancer vaccines currently in clinical development? What are their happenings, platform technology, and current developments?



Contents

- 1. EXECUTIVE SUMMARY
- 2. INTRODUCTION TO CANCER VACCINES
- 3. MECHANISM OF CANCER VACCINES
- 4. GLOBAL CANCER VACCINES MARKET SIZE AND FORECAST (2015 2025)
- 5. KEY MARKETED CANCER VACCINES MARKET VALUE (2015 2025)
- 5.1 Gardasil/Gardasil
- 5.2 Cervarix
- 5.3 Provenge
- 5.4 Imlygic
- 6. KEY MARKET DRIVERS AND INHIBITORS OF THE CANCER VACCINES MARKET
- 6.1 Key Market Drivers
- 6.2 Key Market Inhibitors
- 7. FUNDING IN THE CANCER VACCINES RESEARCH
- 8. MAJOR DEALS AND AGREEMENT HAPPENINGS IN THE CANCER VACCINES MARKET
- 8.1 Collaboration Deals
- 8.2 Licensing Agreement
- 8.3 Partnership Deals
- 8.4 Merger & Acquisitions
- 9. REGULATORY ENVIRONMENT CANCER VACCINES APPROVAL PROCESS
- 9.1 United States
- 9.2 Europe
- 9.3 Japan



10. KEY PLAYERS ANALYSIS

- 10.1 Merck & Co., Inc.
 - 10.1.1 Business Overview
 - 10.1.2 Vaccines Portfolio
 - 10.1.3 Recent Development
- 10.2 GlaxoSmithKline (GSK)
 - 10.2.1 Business Overview
 - 10.2.2 Vaccines Portfolio
- 10.3 Dendreon Pharmaceuticals (Sanpower Group)
 - 10.3.1 Business Overview
 - 10.3.2 Vaccines Portfolio
 - 10.3.3 Recent Development
- 10.4 Amgen
 - 10.4.1 Business Overview
 - 10.4.2 Vaccines Portfolio
 - 10.4.3 Recent Development

11. EMERGING PLAYERS ANALYSIS

- 11.1 Genocea Biosciences, Inc
 - 11.1.1 Business Overview
 - 11.1.2 Promising Cancer Vaccines in the Clinical Development
 - 11.1.3 Recent Development
- 11.2 GeoVax. Inc
 - 11.2.1 Business Overview
 - 11.2.2 Promising Cancer Vaccines in the Clinical Development
 - 11.2.3 Recent Development
- 11.3 Moderna, Inc
 - 11.3.1 Business Overview
 - 11.3.2 Promising Cancer Vaccines in the Clinical Development
 - 11.3.3 Recent Development
- 11.4 Northwest Biotherapeutics, Inc
 - 11.4.1 Business Overview
 - 11.4.2 Promising Vaccines in the Clinical Development
 - 11.4.3 Recent Development
- 11.5 OncBioMune Pharmaceuticals, Inc.
 - 11.5.1 Business Overview



- 11.5.2 Promising Vaccines in the Clinical Development
- 11.5.3 Recent Development
- 11.6 Inovio Pharmaceuticals, Inc.
 - 11.6.1 Business Overview
 - 11.6.2 Promising Cancer Vaccines in the Clinical Development
 - 11.6.3 Recent Development
- 11.7 Enochian Biosciences
 - 11.7.1 Business Overview
 - 11.7.2 Promising Cancer Vaccines in the Clinical Development
- 11.8 Flow Pharma, Inc.
 - 11.8.1 Business Overview
 - 11.8.2 Promising Cancer Vaccines in the Clinical Development
 - 11.8.3 Recent Development
- 11.9 Polynoma LLC
 - 11.9.1 Business Overview
 - 11.9.2 Promising Cancer Vaccines in the Clinical Development
 - 11.9.3 Recent Development
- 11.10 IO Biotech
 - 11.10.1 Business Overview
 - 11.10.2 Promising Cancer Vaccines in the Clinical Development
 - 11.10.3 Recent Development
- 11.11 Eu Biologics Co., Ltd.
 - 11.11.1 Business Overview
 - 11.11.2 Promising Cancer Vaccines in the Clinical Development
- 11.12 OncoPep, Inc
 - 11.12.1 Business Overview
 - 11.12.2 Promising Cancer Vaccines in the Clinical Development
 - 11.12.3 Recent Development
- 11.13 Medigen, Inc
 - 11.13.1 Business Overview
 - 11.13.2 Promising Cancer Vaccines in the Clinical Development
- 11.14 EVOQ Therapeutics
 - 11.14.1 Business Overview
 - 11.14.2 Promising Cancer Vaccines in the Clinical Development
- 11.15 Heat Biologics, Inc
 - 11.15.1 Business Overview
 - 11.15.2 Promising Cancer Vaccines in the Clinical Development
 - 11.15.3 Recent Development
- 11.16 ViciniVax



- 11.16.1 Business Overview
- 11.16.2 Promising Cancer Vaccines in the Clinical Development
- 11.17 ImmuneTune
 - 11.17.1 Business Overview
- 11.17.2 Promising Cancer Vaccines in the Clinical Development
- 11.18 Elios Therapeutics LLC
 - 11.18.1 Business Overview
 - 11.18.2 Promising Cancer Vaccines in the Clinical Development
 - 11.18.3 Recent Development
- 11.19 Treos Bio Limited
 - 11.19.1 Business Overview
 - 11.19.2 Promising Cancer Vaccines in the Clinical Development
- 11.19.3 Recent Development
- 11.20 Scancell Holdings PLC
 - 11.20.1 Business Overview
 - 11.20.2 Promising Cancer Vaccines in the Clinical Development
- 11.20.3 Recent Development
- 11.21 EpiThany
 - 11.21.1 Business Overview
 - 11.21.2 Promising Cancer Vaccines in the Clinical Development
 - 11.21.3 Recent Development
- 11.22 CureVac AG
 - 11.22.1 Business Overview
 - 11.22.2 Promising Cancer Vaccines in the Clinical Development
- 11.22.3 Recent Development
- 11.23 DCprime
 - 11.23.1 Business Overview
 - 11.23.2 Promising Cancer Vaccines in the Clinical Development
- 11.23.3 Recent Development
- 11.24 Vaximm AG
 - 11.24.1 Business Overview
 - 11.24.2 Promising Cancer Vaccines in the Clinical Development
 - 11.24.3 Recent Development
- 11.25 Anixa Biosciences, Inc.
- 11.25.1 Business Overview
- 11.25.2 Promising Cancer Vaccines in the Clinical Development
- 11.25.3 Recent Development
- 11.26 AdaptVac
- 11.26.1 Business Overview



- 11.26.2 Promising Cancer Vaccines in the Clinical Development
- 11.26.3 Recent Development
- 11.27 PDC*line Pharma
 - 11.27.1 Business Overview
 - 11.27.2 Promising Cancer Vaccines in the Clinical Development
 - 11.27.3 Recent Development
- 11.28 MimiVax LLC
 - 11.28.1 Business Overview
 - 11.28.2 Promising Cancer Vaccines in the Clinical Development
 - 11.28.3 Recent Development
- 11.29 Agenus, Inc
 - 11.29.1 Business Overview
 - 11.29.2 Promising Cancer Vaccines in the Clinical Development
- 11.30 AlphaVax, Inc
 - 11.30.1 Business Overview
- 11.30.2 Promising Cancer Vaccines in the Clinical Development
- 11.31 Genexine
 - 11.31.1 Business Overview
- 11.31.2 Promising Cancer Vaccines in the Clinical Development
- 11.31.3 Recent Development
- 11.32 Globelmmune, Inc
 - 11.32.1 Business Overview
 - 11.32.2 Promising Cancer Vaccines in the Clinical Development
- 11.33 Ubivac, Inc
 - 11.33.1 Business Overview
 - 11.33.2 Promising Cancer Vaccines in the Clinical Development
- 11.34 Vaccinogen, Inc
 - 11.34.1 Business Overview
 - 11.34.2 Promising Cancer Vaccines in the Clinical Development
- 11.35 OSE Immunotherapeutics
 - 11.35.1 Business Overview
 - 11.35.2 Promising Cancer Vaccines in the Clinical Development
 - 11.35.3 Recent Development



List Of Figures

LIST OF FIGURES:

Figure 4-1: Global Cancer Vaccin	es Market Size	(Million US\$)	. 2015 -	- 2019
----------------------------------	----------------	----------------	----------	--------

- Figure 4–2: Global Cancer Vaccines Market Forecast (Million US\$), 2020 2025
- Figure 5–1: Gardasil/Gardasil 9 Market Value Analysis (Million US\$), 2015 2019
- Figure 5–2: Gardasil/Gardasil 9 Market Value Forecast (Million US\$), 2020 2025
- Figure 5–3: Cervarix Market Value Analysis (Million US\$), 2015 2019
- Figure 5–4: Cervarix Market Value Forecast (Million US\$), 2020 2025
- Figure 5-5: Provenge Market Value Analysis (Million US\$), 2015 2019
- Figure 5–6: Provenge Market Value Forecast (Million US\$), 2020 2025
- Figure 5–7: Imlygic Market Value Analysis (Million US\$), 2016 2019
- Figure 5–8: Imlygic Market Value Forecast (Million US\$), 2020 2025



List Of Tables

LIST OF TABLES:

- Table 8–1: Collaboration Deals in the Cancer Vaccines Market
- Table 8–2: Licensing Agreement in the Cancer Vaccines Market
- Table 8–3: Partnership Deals in the Cancer Vaccines Market
- Table 8–4: Merger & Acquisitions in the Cancer Vaccines Market
- Table 9–1: United States Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
- Table 9–2: European Union Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
- Table 9–3: Japan Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
- Table 11–1: Genocea Biosciences, Inc Promising Cancer Vaccines in the Clinical Development
- Table 11–2: GeoVax, Inc Promising Cancer Vaccines in the Clinical Development
- Table 11–3: Moderna, Inc Promising Cancer Vaccines in the Clinical Development
- Table 11–4: Northwest Biotherapeutics, Inc Promising Cancer Vaccines in the Clinical Development
- Table 11–5: OncBioMune Pharmaceuticals, Inc Promising Cancer Vaccines in the Clinical Development
- Table 11–6: Inovio Pharmaceuticals, Inc Promising Cancer Vaccines in the Clinical Development
- Table 11–7: Enochian Biosciences Promising Cancer Vaccines in the Clinical Development
- Table 11–8: Flow Pharma, Inc Promising Cancer Vaccines in the Clinical Development
- Table 11–9: Polynoma LLC Promising Cancer Vaccines in the Clinical Development
- Table 11–10: IO Biotech Promising Cancer Vaccines in the Clinical Development
- Table 11–11: Eu Biologics Co., Ltd. Promising Cancer Vaccines in the Clinical Development
- Table 11–12: OncoPep Promising Cancer Vaccines in the Clinical Development
- Table 11–13: Medigen, Inc Promising Cancer Vaccines in the Clinical Development
- Table 11–14: EVOQ Therapeutics Promising Cancer Vaccines in the Clinical Development
- Table 11–15: Heat Biologics, Inc Promising Cancer Vaccines in the Clinical Development
- Table 11–16: Vicinivax Promising Cancer Vaccines in the Clinical Development
- Table 11–17: ImmuneTune Promising Cancer Vaccines in the Clinical Development



- Table 11–18: Elios Therapeutics Promising Cancer Vaccines in the Clinical Development
- Table 11–19: Treos Bio Limited Promising Cancer Vaccines in the Clinical Development
- Table 11–20: Scancell Holdings PLC Promising Cancer Vaccines in the Clinical Development
- Table 11–21: EpiThany Promising Cancer Vaccines in the Clinical Development
- Table 11–22: CureVac AG Promising Cancer Vaccines in the Clinical Development
- Table 11–23: DCprime Promising Cancer Vaccines in the Clinical Development
- Table 11–24: Vaximm AG Promising Cancer Vaccines in the Clinical Development
- Table 11–25: Anixa Biosciences, Inc Promising Cancer Vaccines in the Clinical Development
- Table 11–26: AdaptVac Promising Cancer Vaccines in the Clinical Development
- Table 11–27: PDC*line Pharma Promising Cancer Vaccines in the Clinical Development
- Table 11–28: MimiVax LLC Promising Cancer Vaccines in the Clinical Development
- Table 11–29: Agenus, Inc Promising Cancer Vaccines in the Clinical Development
- Table 11–30: AlphaVax Promising Cancer Vaccines in the Clinical Development
- Table 11–31: Genexine Promising Cancer Vaccines in the Clinical Development
- Table 11–32: Globelmmune, Inc Promising Cancer Vaccines in the Clinical Development
- Table 11–33: Ubivac Promising Cancer Vaccines in the Clinical Development
- Table 11–34: Vaccinogen Promising Cancer Vaccines in the Clinical Development
- Table 11–35: OSE Immunotherapeutics Promising Cancer Vaccines in the Clinical

Development



I would like to order

Product name: Cancer Vaccines Market, Pipeline Analysis Report 2020 Product link: https://marketpublishers.com/r/C11B00AA8E60EN.html

Price: US\$ 1,590.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/C11B00AA8E60EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:	
Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970